We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in Store for Catalyst (CPRX) Stock in Q1 Earnings?
Read MoreHide Full Article
Catalyst Pharmaceuticals, Inc. (CPRX - Free Report) is expected to report first-quarter 2017 results on May 11. Last quarter, the company recorded a positive earnings surprise of 16.67%. Also, it topped expectations in all of the last four quarters with average positive surprise of 14.59%.
Catalyst’s share price has increased 71.4% year to date, compared with the Zacks classified Medical Drugs industry’s gain of 4.9%.
Let’s see how things are shaping up for this announcement.
Factors to Consider
Although Catalyst does not have any revenue-generating product in its portfolio, investor’s focus on pipeline and regulatory updates is expected to retain. Currently, the company has three candidates under development – Firdapse, CPP-115 and CPP-109.
Its lead pipeline candidate Firdapse is being evaluated for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS). In fact, Catalyst started enrolling patients in a second phase III study (LMS-003) on Firdapse for LEMS (LMS-003) in Dec 2016. The company reached an agreement with the FDA under a Special Protocol Assessment (SPA) for protocol design, clinical endpoints and statistical analysis in Oct 2016.
Top-line data from the study are anticipated in the second half of 2017. Notably, a positive outcome would allow the company to resubmit the new drug application (NDA) for Firdapse for the treatment of LEMS in the same period.
Additionally, Catalyst is working on developing Firdapse for additional indications. In Feb 2016, the company initiated an investigator-sponsored phase II/III study on Firdapse for the symptomatic treatment of MuSK-antibody positive MG. In March, it reported top-line data from the phase II/III trial that showed statistically significant results. According to the investigators the data showed a large clinical benefit to patients.
Apart from Firdapse, Catalyst is also exploring the possibility of developing CPP-115 (a GABA aminotransferase inhibitor) for the treatment of epilepsy (initially infantile spasms) and the other selected neurological indications such as complex partial seizures and Tourette’s disorder. Moreover, it is working on a generic version of Sabril (vigabatrin)- CP-109, which is marketed by Lundbeck Inc. for the treatment of infantile spasms and complex partial seizures.
Earnings Whispers
Our proven model does not conclusively show earnings beat for Catalystis this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here, as you will see below.
Zacks ESP: Catalysthas an Earnings ESP of 0.00%. That is because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at a loss of 6 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Catalyst carries a Zacks Rank #3, which increases the predictive power of ESP. However, we need to have a positive ESP to be confident about an earnings beat.
Note that we caution against stocks with Zacks Ranks #4 or 5 (Sell rated) going into an earnings announcement, especially when the company is seeing a negative estimate revision.
Catalyst Pharmaceuticals, Inc. Price and EPS Surprise
Here are some companies to consider as our model shows that they have the right combination of elements to post an earnings beat in the upcoming quarter:
Fibrogen Inc. (FGEN - Free Report) has an Earnings ESP of +23.81% and a Zacks Rank #3. The company is expected to release results on May 8.
Editas Medicine, Inc. (EDIT - Free Report) has an Earnings ESP of +33.33% and a Zacks Rank #3. The company is expected to release results on May 15.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course. Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
What's in Store for Catalyst (CPRX) Stock in Q1 Earnings?
Catalyst Pharmaceuticals, Inc. (CPRX - Free Report) is expected to report first-quarter 2017 results on May 11. Last quarter, the company recorded a positive earnings surprise of 16.67%. Also, it topped expectations in all of the last four quarters with average positive surprise of 14.59%.
Catalyst’s share price has increased 71.4% year to date, compared with the Zacks classified Medical Drugs industry’s gain of 4.9%.
Let’s see how things are shaping up for this announcement.
Factors to Consider
Although Catalyst does not have any revenue-generating product in its portfolio, investor’s focus on pipeline and regulatory updates is expected to retain. Currently, the company has three candidates under development – Firdapse, CPP-115 and CPP-109.
Its lead pipeline candidate Firdapse is being evaluated for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS). In fact, Catalyst started enrolling patients in a second phase III study (LMS-003) on Firdapse for LEMS (LMS-003) in Dec 2016. The company reached an agreement with the FDA under a Special Protocol Assessment (SPA) for protocol design, clinical endpoints and statistical analysis in Oct 2016.
Top-line data from the study are anticipated in the second half of 2017. Notably, a positive outcome would allow the company to resubmit the new drug application (NDA) for Firdapse for the treatment of LEMS in the same period.
Additionally, Catalyst is working on developing Firdapse for additional indications. In Feb 2016, the company initiated an investigator-sponsored phase II/III study on Firdapse for the symptomatic treatment of MuSK-antibody positive MG. In March, it reported top-line data from the phase II/III trial that showed statistically significant results. According to the investigators the data showed a large clinical benefit to patients.
Apart from Firdapse, Catalyst is also exploring the possibility of developing CPP-115 (a GABA aminotransferase inhibitor) for the treatment of epilepsy (initially infantile spasms) and the other selected neurological indications such as complex partial seizures and Tourette’s disorder. Moreover, it is working on a generic version of Sabril (vigabatrin)- CP-109, which is marketed by Lundbeck Inc. for the treatment of infantile spasms and complex partial seizures.
Earnings Whispers
Our proven model does not conclusively show earnings beat for Catalystis this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here, as you will see below.
Zacks ESP: Catalysthas an Earnings ESP of 0.00%. That is because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at a loss of 6 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Catalyst carries a Zacks Rank #3, which increases the predictive power of ESP. However, we need to have a positive ESP to be confident about an earnings beat.
Note that we caution against stocks with Zacks Ranks #4 or 5 (Sell rated) going into an earnings announcement, especially when the company is seeing a negative estimate revision.
Catalyst Pharmaceuticals, Inc. Price and EPS Surprise
Catalyst Pharmaceuticals, Inc. Price and EPS Surprise | Catalyst Pharmaceuticals, Inc. Quote
Stocks to Consider
Here are some companies to consider as our model shows that they have the right combination of elements to post an earnings beat in the upcoming quarter:
Ultragenyx Pharmaceutical Inc. (RARE - Free Report) has an Earnings ESP of +0.59% and a Zacks Rank #3. The company is expected to release results on May 4. You can see the complete list of today’s Zacks #1 Rank stocks here.
Fibrogen Inc. (FGEN - Free Report) has an Earnings ESP of +23.81% and a Zacks Rank #3. The company is expected to release results on May 8.
Editas Medicine, Inc. (EDIT - Free Report) has an Earnings ESP of +33.33% and a Zacks Rank #3. The company is expected to release results on May 15.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>